The Effects of Pentoxifylline on Peritoneal Functions and Cytokine Levels in Patients Followed with Continuous Ambulatory Peritoneal Dialysis

OBJECTIVE: Continuous Ambulatory Peritoneal Dialysis is more frequently used as renal replacement therapy for end stage renal failure patients. The aim of this study was to evaluate the effects of pentoxifylline on cytokines and permeability of peritoneum in continuous ambulatory peritoneal dialysis patients.MATERIAL and METHODS: 21 patients with peritoneal dialysis followed at ukurova University Department of Nephrology were included. Pentoxifylline was given 2x400 mg daily for three weeks in addition to the standard therapy. All of the patient characteristics such as age, sex, accompanied disease, duration of peritoneal dialysis, edema, body weight, drugs were recorded. Peritoneal equilibration test was done before and after pentoxifylline therapy. Kt/Vurea and creatinine clearance were calculated. Peritoneal transport type, ultrafiltrate and urine volumes and peritoneal sodium excretion were determined.RESULTS: There was no difference for the Kt/Vurea, creatinine clearence, the serum and peritoneal dialysate levels of BUN, creatinine, sodium, albumin, IL-1, IL-6, IL-10, TNF-alpha, beta-2 microglobulin between baseline and after the pentoxifylline therapy. Additionally, there was no difference for measured parameters in diabetic and nondiabetic groups. Relationships between peritoneal sodium excretion and Kt/Vurea, ultrafiltration and sum of urine volume+ultrafiltrate were not found. There was a statistically significant negative correlation between serum albumin and serum IL-10 levels at baseline and after pentoxifylline therapy (p; 0,049).CONCLUSION: Pentoxifylline was not found to be effective in peritoneal permeability. This may be related to the short duration of pentoxifylline therapy and/or the relatively small number of the patients.